Tafamidis Meglumine Patent Expiration

Tafamidis Meglumine is Used for treating the cardiomyopathy associated with transthyretin-mediated amyloidosis. It was first introduced by Foldrx Pharmaceuticals Llc A Wholly Owned Sub Of Pfizer Inc in its drug Vyndaqel on May 3, 2019.


Tafamidis Meglumine Patents

Given below is the list of patents protecting Tafamidis Meglumine, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Vyndaqel US7214695 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding Dec 19, 2024 Foldrx Pharms
Vyndaqel US7214696 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding Dec 19, 2024 Foldrx Pharms
Vyndaqel US8168663 Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof Dec 19, 2023

(Expired)

Foldrx Pharms
Vyndaqel US8653119 Methods for treating transthyretin amyloid diseases Dec 19, 2023

(Expired)

Foldrx Pharms


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tafamidis Meglumine's patents.

Given below is the list recent legal activities going on the following patents of Tafamidis Meglumine.

Event Date Patent/Publication
Patent litigations
Second letter to regulating agency to determine regulatory review period 29 Apr, 2024 US7214696
Second letter to regulating agency to determine regulatory review period 29 Apr, 2024 US7214695
Letter from FDA or Dept of Agriculture re PTE application 08 Feb, 2024 US7214695
Letter from FDA or Dept of Agriculture re PTE application 08 Feb, 2024 US7214696
Payment of Maintenance Fee, 12th Year, Large Entity 18 Oct, 2023 US8168663
Interim Patent Term Extension Granted 13 Oct, 2023 US7214695
Interim Patent Term Extension Granted 13 Oct, 2023 US7214696
Email Notification 23 Aug, 2023 US8168663
Change in Power of Attorney (May Include Associate POA) 23 Aug, 2023 US8168663
Change in Power of Attorney (May Include Associate POA) 22 Aug, 2023 US8653119



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳